By Sahil Pandey June 24 (Reuters) - ALZpath said on Wednesday it had signed a global licensing agreement with Abbott ...

Abbott has become the latest company to team up with Alzheimer’s disease blood test developer ALZpath. | Abbott has become ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

Abbott Laboratories reported organic sales growth of 35% in its diagnostics unit on the back of strong demand for COVID-19 testing, according to the company’s earnings report released Wednesday ...

Abbott Laboratories narrowed its full-year outlook as sales of COVID-19 tests slide. COVID-19 test sales in the second quarter dropped 46% from the year before. Second-quarter earnings and revenue ...

Abbott Laboratories (NYSE: ABT) is a leader in coronavirus testing. Its laboratory tests and rapid tests have brought in billions of dollars in revenue. In the fourth quarter of last year, for example ...

Abbott Laboratories' fortunes rose in the second quarter through significantly higher sales of rapid COVID tests compared to last year, while its troubled infant formula business fell, the North ...

Jan 26 (Reuters) - Abbott Laboratories (ABT.N), opens new tab on Wednesday beat quarterly profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for its diagnostics ...